Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Astrazeneca Ord Shs
AZNCF
Healthcare
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex...
, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (OTCPK:AZNCF)
New Post
View:
Posts & Comments
Threaded Posts
(276)
•••
whytestocks
X
Post by
whytestocks
on Jul 25, 2024 10:16pm
AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript
News; $AZN AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript2024-07-25 11:45:11 ET Image source: The Motley Fool. AstraZeneca Plc (NASDAQ: AZN) Q2 2024 Earnings Call Jul 25, 2024 , 6:45 a.m. ET
...more
(276)
•••
whytestocks
X
Post by
whytestocks
on Feb 19, 2024 2:30am
Datopotamab Deruxtecan Biologics License Application Accepte
Just In: $AZN Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung CancerApplication based on results
...more
(276)
•••
whytestocks
X
Post by
whytestocks
on Feb 08, 2024 8:30pm
AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript
Breaking News: $AZN AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript2024-02-08 16:15:30 ET Image source: The Motley Fool. AstraZeneca Plc (NASDAQ: AZN) Q4 2023 Earnings Call Feb 08, 2024 , 6:45
...more
(1)
•••
edwardebreen15
X
Post by
edwardebreen15
on Aug 22, 2022 8:57am
Hospital Infection Therapeutics Market Size & Share 2021-26
According to IMARC Group’s latest report, titled “Hospital Infection Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, the global market reached a
...more
(4)
•••
Rejean1
X
Post by
Rejean1
on Jan 29, 2021 3:05pm
Aztra vaccine coming to Canada soon news?
https://www.msn.com/en-ca/news/newspolitics/health-canada-to-decide-on-astrazeneca-covid-19-vaccine-in-coming-days/ar-BB1ddoDT?ocid=mailsignout&li=AAggNb9
(4)
•••
Rejean1
X
Post by
Rejean1
on Jan 29, 2021 2:40pm
Conflicting news???
I thought I just read elsewhere they had banned shots to people over 65? A month after it received approval in the UK, the EU’s regulator declared the vaccine safe for general use across the 27
...more
(4)
•••
Rejean1
X
Post by
Rejean1
on Jan 21, 2021 11:26am
5 dead in Astrazeneca fire in India.
https://www.bbc.com/news/world-asia-india-55753586
(115)
•••
Rossaporino
X
Post by
Rossaporino
on Jan 02, 2021 6:40pm
Happy new year Do your Own DD
https://www.globenewswire.com/news-release/2020/12/31/2151927/0/en/MedMira-Announces-Product-Update.html
(15)
•••
CBalardo
X
Post by
CBalardo
on Jan 02, 2021 3:10pm
Should be a good Q1
Time to load this one into the portfolio. This should go up on hype and revenue in my eyes. India just approved this gig!
(3)
•••
Mil_Man54
X
Post by
Mil_Man54
on Dec 26, 2020 8:17am
Bonvoyage12.....Lying Pumper
Ignore this clown as he posts lies trying to mislead investors about the actual state of the company...he also posts this same BS on multiple boards
(5)
•••
SmallCapPaul
X
Post by
SmallCapPaul
on Oct 06, 2020 1:10pm
👍 The Timing of a COVID Vaccine
https://www.channelchek.com/news-channel/The_Timing_of_a_COVID_Vaccine
(9)
•••
schoolofrock
X
Post by
schoolofrock
on Sep 04, 2020 9:44am
Targeted Therapy - Opportunity to Ditch Chemo?
PARP inhibitors - Astra Zeneca, Tesaro, Clovis, more at: https://www.channelchek.com/news-channel/An_Opportunity_to_Ditch_Chemotherapy_and_Still_Treat_Cancer
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Are PGM mining stocks an attractive area for your next portfolio allocation?
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages